Endless Biotech Welcomes Braz Vaidya as Chief Scientist
News
Endless Biotech announces Braz Vaidya as Chief Scientist, a globally recognized tissue culture expert with over two decades of experience. His leadership will elevate our R&D and help us achieve ambitious goals in plant biotechnology.
Endless Biotech welcomes Braz Vaidya as Chief Scientist, marking a pivotal moment in our growth. With extensive expertise in tissue culture and plant biotechnology, including leading roles at Vida Cann/Planet 13, Braz will spearhead our Tissue Culture operations in Tulsa. His vision aligns with our ambitious target of producing 5 million tissue culture clones monthly.
As a world-renowned innovator, Braz’s leadership will drive innovation, scale operations, and reinforce Endless Biotech’s position as a leader in plant biotechnology.
Endless Biotech is thrilled to announce the appointment of Braz Vaidya as our new Chief Scientist. A world-renowned expert in tissue culture, Braz brings an unparalleled level of expertise to our team, enhancing our research and development efforts as we continue to innovate in the biotechnology space. His leadership will be crucial as we scale our operations and push the boundaries of what's possible in plant biotechnology.
Braz Vaidya joins us from Vida Cann/Planet 13 in St. Johns, FL, where he served as Director of Plant Biotech, leading the design and management of commercial tissue culture labs, overseeing viroid testing, and collaborating with production facilities on groundbreaking trials. With a career spanning over two decades and experience in both national and international projects, Braz's addition to Endless Biotech is a significant milestone in our growth journey. He will be relocating to Tulsa to take over our Tissue Culture operations, and his vision will drive our company to new heights. We look forward to the incredible impact Braz will have on our team and the industry at large.
Gary Holland, President and Chief Operating Officer of Endless Biotech, expressed his excitement about Braz’s arrival, stating:
"With Braz on board, we are poised to meet our ambitious goal of producing 5,000,000 tissue culture clones per month. His expertise in tissue culture and plant biotechnology is exactly what we need to achieve this milestone and continue leading the industry in innovation and growth."
